Pancreatic Cancer Research

ResearcherUniversity of PisaNo recent work listed

Silvia Catanese

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4937-9942; OpenAlex author ID A5026345672. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2016: 2 papers · 2017: none · 2018: none · 2019: 2 papers · 2020: 2 papers · 2021: 2 papers

Papers 8

  1. Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-p… Co-author DOI 10.1038/s41397-020-00203-7↗
  2. Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer. Co-author DOI 10.3390/cancers13153738↗
  3. First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age? Co-author DOI 10.1016/j.ejca.2020.06.031↗
  4. ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer. Co-author DOI 10.1136/esmoopen-2020-000804↗
  5. Combination Chemotherapy in Patients With Advanced Pancreatic Cancer With an Eastern Cooperative Oncology Group Performance Status of 2: Lights and Shadows of … Co-author DOI 10.1200/jco.19.00127↗
  6. Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Coh… Co-author DOI 10.3390/cancers11070939↗
  7. First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors. Co-author DOI 10.1002/ijc.30125↗
  8. Second-line therapy for advanced pancreatic cancer: evaluation of prognostic factors and review of current literature. Co-author DOI 10.2217/fon.16.16↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Caterina Vivaldi · 7 shared papers, 2016–2021 · strength 0.62
  2. Lorenzo Fornaro · 7 shared papers, 2016–2021 · strength 0.62
  3. Enrico Vasile · 7 shared papers, 2016–2021 · strength 0.62
  4. Irene Pecora · 4 shared papers, 2019–2021 · strength 0.39
  5. Eleonora Rofi · 2 shared papers, 2021 · strength 0.23
  6. Marzia Del Re · 2 shared papers, 2021 · strength 0.23
  7. Romano Danesi · 2 shared papers, 2021 · strength 0.23
  8. Florian Lordick · 1 shared paper, 2020 · strength 0.16
  9. George E. Pentheroudakis · 1 shared paper, 2020 · strength 0.16
  10. Chiara Caparello · 2 shared papers, 2016 · strength 0.12
  11. Kalliopi Andrikou · 1 shared paper, 2020 · strength 0.09
  12. Giulia Rovesti · 1 shared paper, 2020 · strength 0.09
  13. Vincenzo Formica · 1 shared paper, 2020 · strength 0.09
  14. Daniela Campani · 1 shared paper, 2019 · strength 0.07
  15. Emanuele F. Kauffmann · 1 shared paper, 2019 · strength 0.07
  16. Andrea Cacciato Insilla · 1 shared paper, 2019 · strength 0.07
  17. Niccolò Napoli · 1 shared paper, 2019 · strength 0.07
  18. Ugo Boggi · 1 shared paper, 2019 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.